Mar 13, 2026 Dermatology Times: Determining Biologic or JAKi Efficacy for Patients With Moderate to Severe AD Through GEP Testing
Mar 12, 2026 The CEO Magazine: Meet the Judges for the 2026 Executive of the Year Awards – United States
Mar 11, 2026 American Journal of Managed Care (AJMC): Gene Expression Profile Helps Predict Atopic Dermatitis Therapy Response
Mar 11, 2026 Dermatology Times: AdvanceAD-Tx Gene Expression Profile Test May Help Guide Systemic Therapy Selection in Atopic Dermatitis
Mar 5, 2026 Pulse 2.0: Castle Biosciences: Interview With Founder, CEO, And President Derek Maetzold About The Molecular Diagnostics Company
Feb 25, 2026 JDNPPA: Castle’s AdvanceAD-Tx Identifies AD Patients Who Are More Likely to Respond to JAK Inhibitors
Feb 20, 2026 The Dermatology Digest: Personalized Medicine in Action: Castle’s AdvanceAD-Tx Identifies AD Patients Who Are More Likely to Respond to JAK Inhibitors
Feb 20, 2026 Dermatology Times: JAAD Study Validates 487-GEP to Guide JAK Inhibitor Selection in Moderate to Severe AD
